OPTIMIZATION OF CULTIVATION CONDITIONS FOR RECOMBINANT INFLUENZA VIRUSES EXPRESSING IMMUNODOMINANT M. BOVIS PROTEINS
Main Article Content
Authors
E. Voronina
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
Zh. Abay
1Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
2I. Arabaev Kyrgyz State University, Bishkek, Kyrgyzstan
A. Nurpeisova
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
B. Abdrakhmanova
Кыргызский государственный университет им. И. Арабаева, г. Бишкек, Киргизия
K. Jekebekov
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
S. Sadikalieva
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
Ye. Bulatov
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
N. Kozhabergenov
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
K. Zakarya
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
K. Shorayeva
Research Institute for Biological Safety Problems, Guardeyskiy uts., Kazakhstan, 2 Аl-Farabi Kazakh National University, Almaty, Kazakhstan
Abstract
The use of recombinant viral vectors is one of the promising approaches to the creation of a new generation of vaccines against bovine tuberculosis. For the prevention of tuberculosis in cattle, two reassortant recombinant strains of influenza A virus expressing mycobacterial proteins ESAT-6 and TB-10.4 were constructed based on the method of reverse genetics. As a result of optimization of virus cultivation conditions, the cytopathic effect of the virus was recorded on the Vero cell culture. It has been established that the maximum accumulation of viruses is noted when cultivating in a Vero cell culture using a serum-free DMEM medium at a temperature of (37 ± 0.5) ºС, with access to 5% carbon dioxide. The peak of the biological activity of the recombinant strains for both samples reached at 72 hours of the study and lasted for 96 hours. The biological activity of FLU NS_ESAT 6 was 7.50 ± 0.08 lg TCD50/cm3 , and for FLU NS_TB10.4 was 7,75 ± 0,08 lg TCD50/cm3. The results obtained are the basis for the development of viral biomass for work on the creation of an experimental series of vaccines against bovine tuberculosis.
Keywords
микобактериальные антигены, рекомбинантный штамм вируса гриппа птиц, культивирование, влияние температуры, культура клеток, Vero, MDCK
Article Details
References
Sergeeva, M.V., Pulkina, A.A., Vasiliev, K.A., Romanovskaya-Romanko, E.A., Komissarov, A.B., Kuchur, O.A., Egorov, A.Yu., Tsybalova, L.M., Stukova, M.A. // Safety and immunogenicity of a cold-adapted influenza vector expressing M. tuberculosis ESAT-6 and Ag85A antigens. Problems of Virology. – 2017. - №62(6). – P.266-272.
Kuchur, O.A. // Molecular and Biological Characteristics of a Vaccine Strain Based on an Influenza Vector Expressing Protective Proteins of Different Phases of the M. tuberculosis Life Cycle. Master's work. – 2018. – P.9-15.
Sedova, E.S., Shcherbinin, D.N., Migunov, A.I., Smirnov, Yu.A., Logunov, D.Yu., Shmarov, M.M., Tsybalova, L.M., Naroditsky, B.S., Kiselev, O.I., Gintsburg, A. L. // Influenza recombinant vaccines. Acta naturae. – 2012. - №4(15). – P.17-26.
Jawinski, K., Hartmann, M., Singh, Ch., Kinnear, E., Busse, D., Ciabattini, A., Fiorino, F., Medaglini, D., Trombetta, C.M., Montomoli, E., Contreras, V., Le Grand, R., Coiffer, C., Primard, Ch., Verrier, B., Tregoring, J. // Recombinant haemagglutinin derived from the ciliated protozoan Tetrahymena thermophila is protective against influenza infection. Sec Vaccines and Molecular Therapeutics. – 2019. - №10. – P.1-14.
Sereinig, S., Stukova, M., Zabolotnyh, N., Ferko, B., Kittel, Ch., Romanova, J., Vinogradova, T., Katinger, H., Kiselev, O., Egorov, A. // Influenza virus NS vectors expressing the Mycobacterium tuberculosis ESAT-6 protein induce CD4 Th1 immune response and protect animals against tuberculosis challenge. Clinical and Vaccine Immunology. – 2006. - №13(8). - P. 898–904.
Ferko, B., Stasakova, J., Sereinig, S., Romanova, J., Katinger, D., Niebler, B., Katinger, H., Egorov, A. // Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. Virology. – 2001. - №75(19). – P.8899–8908.
Reed, L.J, Muench, H. // A simple method of estimating fifty percent endpoints. Am J Hyg. – 1938. - №27. – P.493–497.
WHO manual on animal influenza diagnosis and surveillance // Geneva: World Health Organization. 2002. Available at: URL
de Vries, R.D., Rimmelzwaan, G.F. // Viral vector-based influenza vaccines. Hum Vaccines Immunother. – 2016. - №12. – P.2881–2901.
Buzitskaya, Zh., Stosman, K., Khairullin, B., Kassenov, M., Nurpeisova, A., Sansyzbay, A., Shurygina, A-P., Aleksandrov, A., Sivak, K., Stukova, M. // A new intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: preclinical safety studies. Drug Res (Stuttg). – 2022. - №72(5). – P.255-258.
Shurygina, A-Р., Buzitskaya, Zh., Stukova, М., Khairullin, B., Kassenov, М., Nurpeysova, A., Zabolotnyh, N.V., Vinogradova, T. // Pre-clinical evaluation of a replication-deficient intranasal influenza vector vaccine expressing two Mycobacterium antigens. 45th Union World conference on Lung health, Spain. – 2014. - № 5266.
Stukova, M.A., Khairullin, B.M., Shurygina, A.-P.S., Buzitskaya, Zh.V., Pisareva, M.M., Erofeeva, M.K., Grudinin, M.P., Kasenov, M.M. , Nurpeisova, A.S., Sarsenbayeva, G.Zh., Bogdanov, N.V., Egorov, A.Yu., Sansyzbay, A.R., Kiselev, O.I. // A new approach to the prevention and immunotherapy of tuberculosis: mucosal vaccine based on recombinant influenza vectors. Scientific and practical conference-biennale "Influenza: virology, epidemiology, prevention and treatment". - 2014. – P.27. - St. Petersburg.